Nothing Special   »   [go: up one dir, main page]

PL2714926T3 - Biomarkery raka płuca - Google Patents

Biomarkery raka płuca

Info

Publication number
PL2714926T3
PL2714926T3 PL12723210T PL12723210T PL2714926T3 PL 2714926 T3 PL2714926 T3 PL 2714926T3 PL 12723210 T PL12723210 T PL 12723210T PL 12723210 T PL12723210 T PL 12723210T PL 2714926 T3 PL2714926 T3 PL 2714926T3
Authority
PL
Poland
Prior art keywords
biomarkers
lung cancer
lung
cancer
Prior art date
Application number
PL12723210T
Other languages
English (en)
Inventor
Edoardo Missiaglia
Pratyaksha Wirapati
Simona Rossi
Werner Kroll
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2714926T3 publication Critical patent/PL2714926T3/pl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicinal Preparation (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
PL12723210T 2011-05-25 2012-05-24 Biomarkery raka płuca PL2714926T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161490021P 2011-05-25 2011-05-25
PCT/EP2012/059784 WO2012160177A1 (en) 2011-05-25 2012-05-24 Biomarkers for lung cancer
EP12723210.6A EP2714926B1 (en) 2011-05-25 2012-05-24 Biomarkers for lung cancer

Publications (1)

Publication Number Publication Date
PL2714926T3 true PL2714926T3 (pl) 2015-12-31

Family

ID=46148889

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12723210T PL2714926T3 (pl) 2011-05-25 2012-05-24 Biomarkery raka płuca

Country Status (17)

Country Link
US (1) US20140227372A1 (pl)
EP (1) EP2714926B1 (pl)
JP (1) JP2014516531A (pl)
KR (1) KR20140024907A (pl)
CN (1) CN103562409B (pl)
AU (1) AU2012260785B2 (pl)
BR (1) BR112013029787A2 (pl)
CA (1) CA2836844A1 (pl)
ES (1) ES2550192T3 (pl)
HK (1) HK1193637A1 (pl)
IL (1) IL229319A0 (pl)
MX (1) MX340453B (pl)
PL (1) PL2714926T3 (pl)
PT (1) PT2714926E (pl)
RU (1) RU2013157589A (pl)
SG (1) SG194615A1 (pl)
WO (1) WO2012160177A1 (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
BR112013007862A2 (pt) 2010-10-01 2019-09-24 Moderna Therapeutics Inc ácidos nucleicos manipulados e métodos de uso dos mesmos.
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2850624A1 (en) 2011-10-03 2013-04-11 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US20130156849A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9192651B2 (en) 2012-04-02 2015-11-24 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
MX2017003015A (es) * 2014-09-17 2017-05-23 Merck Patent Gmbh Metodo para tratar canceres solidos y/o metastasis de los mismos, medicamentos para los mismos, y metodo para predecir el resultado clinico para tratar canceres solidos y/o metastasis de los mismos.
WO2016106643A1 (zh) * 2014-12-31 2016-07-07 深圳华大基因股份有限公司 检测非小细胞肺癌用药相关基因突变的引物及检测方法
CN108369234B (zh) * 2015-10-23 2020-12-01 豪夫迈·罗氏有限公司 基于标志物分子将个体鉴定为待通过化疗治疗的方法和相关用途
CN107022605B (zh) * 2017-02-27 2019-10-15 广东医科大学 一种活动性肺结核的生物标志物
CN107142320B (zh) * 2017-06-16 2021-03-09 上海易毕恩基因科技有限公司 用于检测肝癌的基因标志物及其用途
US10788484B2 (en) 2017-06-29 2020-09-29 Quanticision Diagnostics Inc. Apparatus and method for absolute quantification of biomarkers for solid tumor diagnosis
CN109426776A (zh) * 2017-08-25 2019-03-05 微软技术许可有限责任公司 基于深度神经网络的对象检测
CN109470858B (zh) * 2017-09-08 2022-02-15 广州市丹蓝生物科技有限公司 肺癌诊断用蛋白芯片及试剂盒
CN109470854B (zh) * 2017-09-08 2022-02-11 广州市丹蓝生物科技有限公司 肺癌诊断用蛋白芯片及试剂盒
JP2019086348A (ja) * 2017-11-06 2019-06-06 公益財団法人ヒューマンサイエンス振興財団 バイオマーカー及び血液試料中のvegf−c濃度の測定方法
US20210079479A1 (en) * 2017-12-19 2021-03-18 The Wistar Institute Of Anatomy And Biology Compostions and methods for diagnosing lung cancers using gene expression profiles
WO2019147706A1 (en) * 2018-01-23 2019-08-01 National Jewish Health Methods of treating steroid resistant diseases or conditions
CN108931587B (zh) * 2018-04-18 2021-09-07 湖州市中心医院 一种定量筛选nsclc的诊断生物标志物的方法
RU2706116C1 (ru) * 2018-12-26 2019-11-14 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ прогнозирования течения аденокарциномы легкого
GB201901439D0 (en) * 2019-02-01 2019-03-27 Univ London Method of predicting survival rates for cancer patients

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060252057A1 (en) * 2004-11-30 2006-11-09 Mitch Raponi Lung cancer prognostics
CN101111768A (zh) * 2004-11-30 2008-01-23 维里德克斯有限责任公司 肺癌预后
EP1980627A1 (en) * 2007-04-13 2008-10-15 Pangaea Biotech, S.A. Method of determining a chemotherapeutic regime and survival expectancy for non small cell lung cancer based on EGFR/CSF-1/CA IX expression
ATE543913T1 (de) * 2007-06-01 2012-02-15 Agendia B V Prognostische genexpressionssignatur für patienten mit nichtkleinzelligem lungenkrebs
EP2288741B1 (en) * 2008-05-14 2015-01-28 University Health Network Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy
JP2011528221A (ja) * 2008-07-16 2011-11-17 オンコセラピー・サイエンス株式会社 肺癌および食道癌に関する治療標的および予後指標としてのect2癌遺伝子
NO328852B1 (no) * 2008-09-24 2010-05-31 Moss Maritime As Fremgangsmate og system for behandling av gass
US20120004116A1 (en) * 2008-12-04 2012-01-05 Ming-Sound Tsao Methods for biomarker identification and biomarker for non-small cell lung cancer
JP4782854B2 (ja) * 2009-03-10 2011-09-28 ナショナル ヤン−ミン ユニバーシティ 癌患者の潜在的転移能、予後、又は全生存を予測する方法

Also Published As

Publication number Publication date
MX2013013746A (es) 2014-02-27
EP2714926A1 (en) 2014-04-09
BR112013029787A2 (pt) 2017-01-17
WO2012160177A1 (en) 2012-11-29
CN103562409A (zh) 2014-02-05
AU2012260785A1 (en) 2013-11-14
JP2014516531A (ja) 2014-07-17
AU2012260785B2 (en) 2016-02-11
EP2714926B1 (en) 2015-07-22
RU2013157589A (ru) 2015-06-27
CA2836844A1 (en) 2012-11-29
SG194615A1 (en) 2013-12-30
PT2714926E (pt) 2015-11-03
US20140227372A1 (en) 2014-08-14
CN103562409B (zh) 2016-04-27
ES2550192T3 (es) 2015-11-05
KR20140024907A (ko) 2014-03-03
MX340453B (es) 2016-07-08
HK1193637A1 (en) 2014-09-26
IL229319A0 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
HK1193637A1 (en) Biomarkers for lung cancer
IL252163A0 (en) Lung cancer biomarkers and their uses
EP2718721A4 (en) CIRCULATING BIOMARKERS FOR CANCER
EP2841603A4 (en) METHODS OF ASSESSING THE STATUS OF LUNG CANCER
EP2758080A4 (en) ANTICANCER IMMUNOTHERAPY
EP2739754A4 (en) MICRO-RNA biomarkers
EP2698634A4 (en) BIOMARKER FOR BREAST CANCER
PL2931922T3 (pl) Personalizowane biomarkery nowotworu
EP2668295A4 (en) METHODS OF DETECTING LUNG CANCER
EP2748608A4 (en) LUNG CANCER TESTS
GB201120860D0 (en) Cancer immunotherapy
EP2691545A4 (en) METHOD FOR CLASSIFYING LUNG CANCER
EP2758777A4 (en) PROOF OF EGG CANCER
GB2494580B (en) Method for diagnosing lung cancer
EP2742358A4 (en) METHOD FOR THE DIAGNOSIS OF CANCER
WO2012167112A9 (en) Gastric cancer biomarkers
EP2707721A4 (en) BIOMARKERS PREDICTIVE FOR PROSTATE CANCER
EP2753716A4 (en) NEW RISK BIO MARKERS FOR LUNG CANCER
GB2510539B (en) Biomarkers of cancer
IL231556A (en) Biological markers for respiratory tract infection
GB201104556D0 (en) Biomarkers
HK1177502A1 (en) Biomarker for gastric cancer
EP2769225A4 (en) BIOLOGICAL MARKERS PREDICTIVE FOR BREAST CANCER
GB201107675D0 (en) Prognostic biomarkers for lung diseases
GB201119196D0 (en) Biomarkers